CNTX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	19 946.00
平均成交量	55 784.00
市值	22.51M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $-0.390 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.940
ATR14	$0.0230 (1.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Minai-azary Jennifer Lynn	Buy	160 115	Stock Option (right to buy)
2024-03-21	Levit Alex C.	Buy	153 515	Stock Option (right to buy)
2024-03-21	Lehr Martin A.	Buy	291 402	Stock Option (right to buy)
2023-05-31	Kantoff Philip W.	Buy	25 000	Stock Option (right to buy)
2023-05-31	West Linda	Buy	25 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 4 162 098 \| Sell: 2 098 089

Context Therapeutics Inc. 相关性

10 最正相关
SGH	0.957
KOPN	0.957
PLAB	0.949
ALR	0.941
STER	0.939
ELTK	0.938
MRVL	0.935
XBIT	0.931
EVLO	0.927
CALA	0.927

10 最负相关
OPTN	-0.919
SBNYP	-0.909
ASO	-0.901
FANH	-0.899
ATHN	-0.896
PHCF	-0.895
CDAK	-0.885
PAYS	-0.885
MTSI	-0.877
AGFS	-0.876

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Context Therapeutics Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2023
营收:	$0
毛利润:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2022
营收:	$0
毛利润:	$-9 268.00 (0.00 %)
EPS:	$-0.900

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.024

Financial Reports:

No articles found.

Context Therapeutics Inc.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.